Braunstein and Richter Talk Transplant and Therapy Options in Newly Diagnosed Myeloma

January 7, 2021
OncLive Staff

Partner | Cancer Centers | <b>Perlmutter Cancer Center at NYU Langone</b>

In our exclusive interview, Dr. Braunstein and Dr. Richter discuss navigating treatment selection for patients with the newly diagnosed multiple myeloma and the evolving role of minimal residual disease testing.

Welcome to OncLive On Air! I’m your host today, Jessica Hergert.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Marc J. Braunstein, MD, PhD, assistant professor in the Department of Medicine at NYU Long Island School of Medicine, course co-director of the Hematology-Oncology System and co-director of the Autologous Stem Cell Transplant Program at NYU Winthrop Hospital of NYU Langone Health’s Perlmutter Cancer Center, and Joshua Richter, MD, an assistant professor of medicine, and a hematologist/oncologist at Mount Sinai Hospital, to discuss the elements of treatment selection in newly diagnosed multiple myeloma.

In our exclusive interview, Braunstein and Richter discussed navigating treatment selection for patients with the newly diagnosed multiple myeloma and the the evolving role of MRD testing.

Related Content:

Podcasts | Multiple Myeloma

x